Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Arundic acid - Ono Pharmaceutical

X
Drug Profile

Arundic acid - Ono Pharmaceutical

Alternative Names: Arocyte Injection; Cereact Capsule; MK-0724; ONO-2506; ONO-2506PO; Proglia®

Latest Information Update: 18 Mar 2010

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ono Pharmaceutical
  • Developer Merck & Co; Ono Pharmaceutical
  • Class Neuroprotectants; Nootropics; Octanoic acids; Small molecules
  • Mechanism of Action Astrocyte modulators; Cyclo-oxygenase 2 inhibitors; Free radical scavengers; Nitric oxide synthase type II inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease; Amyotrophic lateral sclerosis; Parkinson's disease; Stroke

Most Recent Events

  • 01 Nov 2006 This compound is still in active development for Alzheimer's disease in Japan
  • 01 Nov 2006 Data presented at the 36th Annual Meeting of the Society for Neuroscience (SfN-2006) have been added to the Alzheimer's disease pharmacodynamics section
  • 18 Aug 2006 Commencement of phase-II clinical trials in Stroke planned in North America (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top